Kidney Transplant Rejection Market Demand Forecast and Leading Players Analysis Through 2030

 

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.
 
 How Strong Is the Market Growth Outlook for the Kidney Transplant Rejection Market?
 The kidney transplant rejection market size has grown strongly in recent years. It will grow from $3.51 billion in 2025 to $3.76 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increasing kidney transplant procedures, advancements in histopathological assessment techniques, wider availability of immunosuppressive drugs, growth of transplant center networks, improving post-transplant patient survival rates.
 
 The kidney transplant rejection market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized immunosuppression strategies, increasing adoption of molecular diagnostics, expansion of precision medicine in transplant care, growing focus on long-term graft survival, increasing investment in transplant monitoring technologies. Major trends in the forecast period include increasing adoption of biomarker-based rejection monitoring, rising use of genomics-based diagnostic approaches, growing optimization of immunosuppressive therapy protocols, expansion of non-invasive rejection surveillance methods, enhanced focus on early detection of chronic rejection.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report
 
 Which Major Growth Drivers Will Influence the Kidney Transplant Rejection Market by 2030?
 The rising incidence of end‑stage renal disease is expected to propel the growth of the kidney transplant rejection market going forward. End‑stage renal disease (ESRD) refers to the final, irreversible stage of chronic kidney disease in which the kidneys fail to function adequately without dialysis or a kidney transplant. The incidence of end‑stage renal disease is rising due to the increasing prevalence of chronic conditions, diabetes and hypertension, which progressively damage the kidneys and lead to kidney failure. Kidney transplant rejection drives the need for advanced monitoring and therapeutic interventions, directly supporting the management of end‑stage renal disease by ensuring transplanted kidneys remain functional and patients maintain kidney health. For instance, in September 2024, according to the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, in 2023, more than 808,000 people in the United States were living with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD), with 68% receiving dialysis and 32% having undergone a kidney transplant. Therefore, the rising incidence of end-stage renal disease is driving the growth of the kidney transplant rejection market.
 
 What Segment Categories Define the Kidney Transplant Rejection Market Structure?
 The kidney transplant rejection market covered in this report is segmented — 
 
 1) By Rejection Type: Chronic Rejection; Acute Rejection
 2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies
 3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics
 4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies
 5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies
 
 Subsegments:
 1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection
 2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection
 
 What Are the Key Industry Trends Transforming the Kidney Transplant Rejection Market?
 Major companies operating in the kidney transplant rejection market are focusing on developing innovative diagnostic solutions, such as noninvasive urinary biomarker testing, to enable faster, safer, and more accurate detection of transplant rejection. Noninvasive urinary biomarker testing analyzes urine samples to detect molecular indicators of kidney inflammation or rejection, helping clinicians identify transplant complications quickly and safely without the need for invasive biopsies. For instance, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, launched the CXCL10 testing service, an innovative diagnostic tool for kidney transplant recipients. The CXCL10 test detects the CXCL10 chemokine in urine, which is associated with early transplant rejection and inflammation. It delivers results within 24 hours, enabling quicker clinical decisions, reducing the need for unnecessary biopsies, and improving patient convenience by utilizing noninvasive sample collection. Developed and validated by Thermo Fisher’s One Lambda Laboratories, the assay combines high sensitivity and specificity with ease of use in clinical settings, supporting better post-transplant care and patient outcomes.
 
 Which Players Dominate the Kidney Transplant Rejection Market Landscape?
 Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc. 
 
 Get the full kidney transplant rejection market report here:
 https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report
 
 How does the Kidney Transplant Rejection Market perform across different regions?
 North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company